1. 1142PDEfficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort. (23rd October 2018) Authors: Domblides, C; Monnet, I; Mazieres, J; Barlesi, F; Gounant, V; Baldacci, S; Mennecier, B; Toffart, A C; Audigier Valette, C; Doucet, L; Giroux-Leprieur, E; Guisier, F; Molinier, O; Perol, M; Pichon, E; Robinet, G; Templement Grangerat, D; Ruppert, A-M; Wislez, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 125PMolecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study. (23rd October 2018) Authors: Blons, H; Oudart, J-B; Merlio, J-P; Hominal, S; de Fraipont, F; Debieuvre, D; Escande, F; Audigier Valette, C; Bringuier, P-P; Moreau Fraboulet, S; Ouafik, L; Moro-Sibilot, D; Lemoine, A; Langlais, A; Missy, P; Morin, F; Souquet, P-J; Barlesi, F; Cadranel, J; Beau-Faller, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Santoro, A; Su, W-C; Navarro, A; Simonelli, M; Yang, J C-H; Ardizzoni, A; Barlesi, F; Kang, J H; Didominick, S; Abdelhady, A; Goswami, B; Crystal, A; Felip, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1469PEVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients. (23rd October 2018) Authors: Dixmier, A; Debieuvre, D; Raspaud, C; Auliac, J B; Benoit, N; Bombaron, P; Asselain, B; Dumont, A; Lamoureux, P; Goyard, N; Moro-Sibilot, D; Perol, M; Barlesi, F; Audigier Valette, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1488PVemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial. (23rd October 2018) Authors: Mazières, J; Montané, L; Barlesi, F; Quantin, X; Trédaniel, J; Le Treut, J; Avrillon, V; Lavolé, A; Westeel, V; Orsini Piocelle, F; Pichon, E; Thiberville, L; Borel, C; Renault, P A; Jaffro, M; Collot, S; Ferretti, G; Legrand, F; Mahier Ait Oukhatar, C; Blay, J Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 182TiPEXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors. (23rd October 2018) Authors: Italiano, A; Le Saux, O; André, F; Filleron, T; Spaeth, D; Heudel, P-E; Albiges, L; Bachelot, T; Gonçalves, A; Pierga, J-Y; Barlesi, F; Boige, V; Lebbe, C; Mortier, L; Frenel, J-S; Tredan, O; Jimenez, M; Legrand, F; Ferté, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 531TiPCANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC. (24th November 2019) Authors: Cho, B C; Chang, G-C; Kim, Y-C; Geater, S; Saeteng, S; Yang, C-T; Goto, Y; Lu, S; Ardizzoni, A; Barlesi, F; De Marchi, P; Paz-Ares, L; Spigel, D R; Thomas, M; Garon, E B; Leung, M; Baum, J; Zewen, Z; Mookerjee, B; Yang, J C-H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 64PEntrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. (24th November 2019) Authors: de Braud, F; Siena, S; Barlesi, F; Drilon, A; Simmons, B; Huang, X; Osborne, S; Doebele, R C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817. (15th December 2019) Authors: Barlesi, F; Audigier-Valette, C; Felip, E; Ciuleanu, T-E; Jao, K; Rijavec, E; Urban, L; Aucoin, J-S; Zannori, C; Vermaelen, K; Frontera, O Arén; Ready, N; Curioni, A; Linardou, H; Poddubskaya, E; Fischer, J R; Pillai, R; Li, S; Acevedo, A; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess. (3rd September 2019) Authors: Ciccolini, J; Barbolosi, D; André, N; Benzekry, S; Barlesi, F Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗